(1R,8S,13S,14R)-14-(2-chloroacetyl)-1,8-difluoro-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl propanoate

• ChemBase编号: 478
• 分子式: C25H31ClF2O5
• 平均质量: 484.9604464
• 单一同位素质量: 484.18280821
• SMILES: ClCC(=O)[C@]1(OC(=O)CC)C2(C(C3[C@](F)(C(O)C2)C2(C(=CC(=O)C=C2)[C@@H](F)C3)C)C[C@@H]1C)C
• Canonical SMILES: CCC(=O)O[C@@]1([C@@H](C)CC2C1(C)CC(O)[C@]1(C2C[C@@H](C2=CC(=O)C=CC12C)F)F)C(=O)CCl
• InChI: InChI=1S/C25H31ClF2O5/c1-5-21(32)33-25(20(31)12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15?,16?,18-,19?,22?,23?,24-,25-/m0/s1
• InChIKey: BDSYKGHYMJNPAB-YKQIDFLYSA-N

名称和登记号

名称

• IUPAC标准名: (1R,8S,13S,14R)-14-(2-chloroacetyl)-1,8-difluoro-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl propanoate
• IUPAC传统名: halobetasol propionate
• 商标名: Halobetasol; Ulobetasol Propionate; Ultravate
• 别名: Halobetasol Propionate

登记号

• CAS号: 66852-54-8
• PubChem SID: 46506187; 160963941
• PubChem CID: 48175

理论计算性质

JChem

• Acid pKa: 13.545719
• 质子受体: 4
• 质子供体: 1
• LogD (pH = 5.5): 3.8381035
• LogD (pH = 7.4): 3.8381033
• Log P: 3.8381035
• 摩尔折射率: 119.1457 cm^3
• 极化性: 46.300114 Å^3
• 极化表面积: 80.67 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 3.81
• LOG S: -4.81
• 溶解度: 7.57e-03 g/l

分子性质

理化性质

• 溶解度: Mostly insoluble
• 疏水性(logP): 2.9

详细说明

DrugBank - DB00596

• Drug Groups: approved
• Description: Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. It is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
• Indication: For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
• Affected Organisms: Humans and other mammals
• Absorption: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
• External Links: RxList; PDRhealth; Drugs.com